Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type I choledochal cysts in adults: natural history and implications for management.

Surgical endoscopy·2026
Same author

Comment on "Association of cardiovascular-kidney-metabolic syndrome with cardiovascular, cancer, and all-cause mortality among US adults: A prospective study".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Comment on "profiling mitochondrial DNA indices across whole blood, plasma, and CSF in amyotrophic lateral sclerosis".

Journal of the neurological sciences·2026
Same author

Hospital Volume and Post-Hepatectomy Liver Failure After Major Hepatectomy.

Journal of surgical oncology·2026
Same author

Clinical trials for hepatocellular carcinoma: are we reaching the most vulnerable patients?

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

Postoperative superior mesenteric artery stenting following pancreaticoduodenectomy in a patient with severe mesenteric atherosclerosis.

Journal of surgical case reports·2026

Related Experiment Video

Updated: Jul 13, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Ezetimibe ameliorates cholecystosteatosis.

Abhishek Mathur1, Julia J Walker, Hayder H Al-Azzawi

  • 1Department of Surgery, Indiana University School of Medicine, Indianapolis, Ind, USA.

Surgery
|August 11, 2007
PubMed
Summary

Ezetimibe treatment reversed gallbladder wall fat accumulation and improved gallbladder emptying in mice. This suggests ezetimibe may be effective in preventing gallstones and treating cholecystosteatosis.

Related Experiment Videos

Last Updated: Jul 13, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Metabolic Research

Background:

  • Cholecystosteatosis, characterized by gallbladder wall fat accumulation and impaired emptying, is a condition with limited therapeutic options.
  • Ezetimibe, known for inhibiting fat absorption and preventing gallstones in mice, has not been previously investigated for its effects on cholecystosteatosis.
  • This study aimed to determine if ezetimibe could improve gallbladder motility and reduce gallbladder wall fat accumulation.

Purpose of the Study:

  • To investigate the therapeutic potential of ezetimibe in ameliorating cholecystosteatosis.
  • To assess the impact of ezetimibe on gallbladder emptying and fat content in the gallbladder wall.
  • To evaluate ezetimibe's efficacy in preventing gallstone formation.

Main Methods:

  • Forty lean female mice were assigned to control or lithogenic diets, with half receiving ezetimibe.
  • Gallbladder ultrasonography was performed to measure ejection fraction.
  • Bile and gallbladder tissue analysis were conducted for cholesterol crystals and lipid content.

Main Results:

  • A lithogenic diet increased serum cholesterol, biliary crystals, gallbladder wall cholesterol, and cholesterol/phospholipid ratio, while decreasing gallbladder ejection fraction.
  • Ezetimibe administration reversed these diet-induced abnormalities.
  • Ezetimibe treatment normalized gallbladder wall fat composition and improved gallbladder function.

Conclusions:

  • Ezetimibe effectively lowers serum cholesterol and prevents biliary crystal formation.
  • The drug normalizes gallbladder wall fat content and restores normal gallbladder function.
  • Ezetimibe demonstrates potential as a therapeutic agent for cholecystosteatosis and gallstone prevention.